EP1848394A1 - Production de formes de dosage a partir de matieres fondues contenant un principe actif - Google Patents

Production de formes de dosage a partir de matieres fondues contenant un principe actif

Info

Publication number
EP1848394A1
EP1848394A1 EP06707060A EP06707060A EP1848394A1 EP 1848394 A1 EP1848394 A1 EP 1848394A1 EP 06707060 A EP06707060 A EP 06707060A EP 06707060 A EP06707060 A EP 06707060A EP 1848394 A1 EP1848394 A1 EP 1848394A1
Authority
EP
European Patent Office
Prior art keywords
melt
films
release
active substance
release films
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP06707060A
Other languages
German (de)
English (en)
Other versions
EP1848394B1 (fr
Inventor
Jörg Rosenberg
Norbert Steiger
Harald Hach
Jörg Breitenbach
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Deutschland GmbH and Co KG
Original Assignee
Abbott GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott GmbH and Co KG filed Critical Abbott GmbH and Co KG
Priority to EP06707060.7A priority Critical patent/EP1848394B1/fr
Publication of EP1848394A1 publication Critical patent/EP1848394A1/fr
Application granted granted Critical
Publication of EP1848394B1 publication Critical patent/EP1848394B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/10—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B30—PRESSES
    • B30B—PRESSES IN GENERAL
    • B30B11/00—Presses specially adapted for forming shaped articles from material in particulate or plastic state, e.g. briquetting presses, tabletting presses
    • B30B11/16—Presses specially adapted for forming shaped articles from material in particulate or plastic state, e.g. briquetting presses, tabletting presses using pocketed rollers, e.g. two co-operating pocketed rollers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J2200/00—General characteristics or adaptations
    • A61J2200/20—Extrusion means, e.g. for producing pharmaceutical forms

Definitions

  • the present invention is a process for the preparation of dosage forms from an active ingredient-containing melt.
  • melt extrusion processes in conjunction with a forming process such as calendering, a process in which the melt in the nip is formed into at least two counter-rotating forming rolls to the desired dosage form, it is critical that the melt not exhibit excessive adhesion to the forming dies, otherwise a demolition will not succeed.
  • forming rollers and calenders are used synonymously below.
  • WO 9707786 describes the use of lipids as an aid in the preparation of solid dosage forms by the melt extrusion process. Between 0.1-10 wt .-% lipids are added to the extrusion mixture as a mold release agent.
  • DE 4446467 describes a process for the production of lenticular tablets by melt calendering. It is referred to in this document that molding rolls can be used, which are provided with a release agent.
  • a release agent for example, a silicone varnish is suitable.
  • EP 0358105 describes a method for shaping extrudate masses. Here are two elastic bands with opposite recesses, which determine the tablet shape used.
  • WO 9619963 describes a process for the production of coated tablets by melt calendering, in which the active substance-containing melt is introduced into the calender forming rolls between two films of the wrapping material.
  • the SU 1824158 describes an apparatus for molding viscoplastic praline masses.
  • the device comprises a hopper with two chambers. Under the hopper, a molding roll with cells for receiving and shaping the chocolate mass is arranged. The forming roll is covered with an elastic band. Under the hopper, a molding roll with cells for receiving and shaping the chocolate mass is arranged. The forming roll is covered with an elastic band. Under the hopper, a molding roll with cells for receiving and shaping the chocolate mass is arranged. The forming roll is covered with an elastic band. Under the hopper, a molding roll with cells for receiving and shaping the chocolate mass is arranged. The forming roll is covered with an elastic band. Under the hopper, a molding roll with cells for receiving and shaping the chocolate mass is arranged. The forming roll is covered with an elastic band. Under the hopper, a molding roll with cells for receiving and shaping the chocolate mass is arranged. The forming roll is covered with an elastic band. Under the hopper, a molding roll with cells for receiving and shaping the chocolate mass is arranged. The
  • JP 02 063699 A discloses a Druckgranuliervorraum with two counter-rotating rollers and two elastic films, which rest at least in the contact region of the rollers on the rollers. Recesses are provided on the surface of the rollers or films. A powder is compressed between the rollers and maintains the shape of the recesses.
  • SU 1824158 nor JP 02 063699 A relates to the formation of melts, d. H. of masses which are plastic at elevated temperature and which solidify on cooling.
  • the invention is based on the object to provide a universally applicable method that allows the formation of active ingredient-containing melts without the problems occurring by sticking the melt on or in the mold.
  • the present invention relates to a process in which two release films are brought together in a defined region, an active substance-containing melt is introduced between the release films so that a pocket for receiving a portion of the melt is formed in at least one of the release films and the release films separated from each other to demold the portion.
  • the release film is expediently brought into contact with the heat-sink, at least in the area of the pocket, with the side facing away from the melt. Heat is removed from the melt via the release film and the melt solidifies. In addition, the thermal load on the release film is reduced and increases its life.
  • the incoming melt usually has a temperature of more than 70 0 C, usually more than 80 ° C, for. B. 80 to 180 0 C.
  • a temperature difference between the melt to be introduced and the heat sink of at least 30 0 C, in particular at least 40 0 C, more preferably at least 50 0 C, a.
  • the release films are brought into contact with one another in the gap of two counter-rotating forming rolls, of which at least one has depressions into which the release film can be pressed to form pockets.
  • both forming rollers on their surface on opposite recesses into which the release films can be pressed to form pockets are particularly preferably, both forming rollers on their surface on opposite recesses into which the release films can be pressed to form pockets.
  • the release film is deformed by the introduced into the trough-shaped space between the mold rolls melt and to the surfaces the wells pressed.
  • the release film prevents direct contact of the melt with the roll surface, so that any adhesion / adhesion of the melt to the surface of the roll can be excluded.
  • the forming rollers also act as heat sinks and are for this purpose made of a highly thermally conductive material, preferably a metal, such as stainless steel or non-ferrous alloys.
  • the heat dissipation can passively be effected by heat radiation from the forming rolls to the environment or by active cooling of the forming rolls, e.g. B. by circulating a coolant through holes in the interior of the molding rolls. Only when the release film is completely pressed into the recess of the mold roll and the bag formed is completely filled with melt, the release film touches the surface of the mold roll. Only then begins a noticeable cooling and solidification of the melt. Premature solidification, which could lead to incomplete filling of the wells with melt, is largely avoided. This gives moldings which are very uniform in their shape and mass.
  • the thickness of the release films used is generally in the range of 0.05 to 1.6 mm, preferably 0.1 to 1 mm and particularly preferably 0.1 to 0.5 mm.
  • the release films of an elastically deformable material since in this case by the relaxation of the release film when leaving the nip, a force occurs, which pushes the molding out of the cavity, so practically ejects the molding.
  • release films with low or negligible elasticity is preferred.
  • the formation of the pockets in the release films can be promoted by a slight softening of the films at the temperatures in the nip.
  • the softening point can be adjusted by the content of plasticizers in the release films.
  • the films are made of an elastomer, they have a tensile strength measured in accordance with DIN EN ISO 527-1 in the range from 3 to 40 MPa, preferably 7 to 30 MPa.
  • the elongation at break according to DIN EN ISO 527-1 is at least 200%, preferably at least 400%.
  • the release films may be passed through the nip by unwinding the film from a roll and winding it onto a second roll after passing through the nip.
  • the release film can be passed behind the roller through a scraper or a cleaning bath.
  • the release films are each closed to form an endless belt, which enables continuous process control.
  • the release film can rest on the outer surface of the forming rollers on the surrounding the mold roller recesses
  • a variant of the method is to lead one or both release films spaced from the nip to the forming rollers and z. B. to lead over adjustable guide rollers in the gap.
  • tensioning screws which are attached to the guide rollers also permit precise adjustment of the thickness of the film in the calendering gap and thus the specific influence on the ejection forces with which the shaped bodies are pressed out of the cavities of the shaping roller.
  • the invention also relates to a device with a mixing and plasticizing unit for the formation of an active ingredient-containing melt and shaping means, which consist of two molding rolls, which have at least one recess for receiving a melt containing active substance.
  • the device is characterized in that the depression comprises a release film which can be reversibly transferred from a rest position into a deflected position by introducing the active substance-containing melt into the depression.
  • the material of the release films may be selected from elastomers and / or water-insoluble thermoplastic polymers.
  • Elastomers such as silicone elastomers, acrylylate rubber, polyester urethane rubber, brominated butyl rubber, polybutadiene, chlorinated butyl rubber, chlorinated polyethylene, epichlorohydrin homo- / copolymer, polychloroprene, sulfurized polyethylene, ethylene Acrylate rubber, ethylene-propylene terpolymer, ethylene-propylene copolymer, polyether-urethane rubber, ethylene-vinyl acetate copolymer, fluorine rubber, fluorosilicone rubber, hydrogenated nitrile rubber, butyl rubber, dimethylpolysiloxane, nitrile rubber (with low, medium, high ACN content, natural rubber, thioplast, polyfluorophosphazenes, polynorbonene, styrene Butadiene rubber and carboxy group-containing nitrile rubbers or mixtures thereof.
  • silicone elastomers such as silicone elast
  • elastomers that are accepted as product-contacting materials in pharmaceutical manufacturing processes, e.g. Silicones. These silicone materials may be produced by addition crosslinking, condensation crosslinking or free radical crosslinking. Other preferred materials are natural rubber and synthetic rubber, with natural rubber being particularly preferred.
  • Preferred release film materials have one or more, preferably all, of the following properties.
  • polyolefins and polyolefin derivatives or copolymers for example polyethylene, polypropylene, polyisobutylene, poly-4-methylpentene and vinyl acetate, vinyl alcohol, acrylic or methacrylic copolymers
  • vinyl polymers eg polystyrene and polystyrene ter and block polymers, eg copolymers of styrene, acrylonitrile and butadiene
  • polyvinyl chloride and copolymers for example copolymers of vinyl chloride and vinyl acetate, methacrylate or acrylonitrile
  • polyvinyl acetate polyvinyl chloride nyl alcohol, polyvinyl methyl ether
  • fluoropolymers such as polytetrafluoroethylene, polyvinyl dienfluorid, polyvinyl fluoride, polyacrylates and methacrylates such as polyacrylonitrile, poly
  • thermoplastic polymers whose softening point is above the temperature of the active substance-containing melt when it enters the calendering gap.
  • preference is given to guiding the film as an endless belt through the calendering gap, since this does not result in any film waste.
  • profiled foils e.g. Noppenfolien
  • geometries of the dosage forms can be further changed.
  • the preparation of the dosage forms is carried out starting from a mixture containing one or more active pharmaceutical ingredients and one or more auxiliaries and which is doughy or viscous by melting or softening at least one component and therefore extrudable.
  • N-vinyl lactams especially homopolymers and copolymers of N-vinyl pyrrolidone, e.g. As polyvinylpyrrolidone (PVP), copolymers of N-vinylpyrrolidone and vinyl acetate or vinyl propionate,
  • PVP polyvinylpyrrolidone
  • Cellulose esters and cellulose ethers in particular methylcellulose and ethylcellulose, hydroxyalkylcelluloses, in particular hydroxypropylcellulose, hydroxyalkylalkylcelluloses, in particular hydroxypropylmethylcellulose, cellulose phthalates or succinates, in particular cellulose acetate phthalate and hydroxypropylmethylcellulose phthalate, hydroxypropylmethylcellulose succinate or hydroxypropylmethylcellulose acetate succinate, High molecular weight polyalkylene oxides such as polyethylene oxide and polypropylene oxide and copolymers of ethylene oxide and propylene oxide,
  • Polyacrylates and polymethacrylates such as methacrylic acid / ethyl acrylate copolymers, methacrylic acid / methyl methacrylate copolymers, butyl methacrylate / 2-dimethylaminoethyl methacrylate copolymers, poly (hydroxyalkyl acrylates), poly (hydroxyalkyl methacrylates),
  • Vinyl acetate polymers such as copolymers of vinyl acetate and crotonic acid, partially hydrolyzed polyvinyl acetate (also referred to as partially saponified polyvinyl alcohol),
  • Oligo- and polysaccharides such as carrageenans, galactomannans and xanthans, or mixtures of one or more thereof.
  • homopolymers or copolymers of vinylpyrrolidone are particularly preferred, for.
  • Active substances in the context of the invention are understood as meaning all substances having a desired physiological action on the human or animal body or plants. These are in particular pharmaceutical active ingredients. The amount of active ingredient per unit dose can vary within wide limits. It is usually chosen so that it is sufficient to achieve the desired effect. Also drug combinations can be used. Active substances within the meaning of the invention are also vitamins and minerals.
  • the vitamins include the vitamins of the A group, the B group, which in addition to B 1 , B 2 , B 6 and B 12 and nicotinic acid and nicotinamide and compounds with vitamin B properties are understood, such. B.
  • Active substances within the meaning of the invention also include peptide therapeutics and proteins.
  • For plant treatment agents include, for. Vinclozolin, epoxiconazole and quinmerac.
  • the process according to the invention is suitable, for example, for processing the following active substances:
  • the mass may also include various optional adjuvants.
  • optional adjuvants are:
  • Plasticizers such. C 7 -C 30 alkanols, ethylene glycol, propylene glycol, glycerol, trimethylolpropane, triethylene glycol, butanediols, pentanols, such as pentaerythritol and hexanols, polyalkylene glycols, preferably having a molecular weight of from 200 to 1000, such as, for example, polyethylene glycols, polypropylene glycols and polyethylene propylene glycols, SiIi cone, aromatic carboxylic acid esters (eg dialkyl phthalates, trimellitic acid esters, benzoic acid esters, terephthalic acid esters) or aliphatic dicarboxylic acid esters (eg dialkyl adipates, sebacic acid esters, azelaic acid esters, citric and tartaric acid esters), fatty acid esters such as glycerol mono-, glycerol di- or
  • the concentration of plasticizer if present, is generally 0.5 to 30, preferably 0.5 to 10,% by weight, based on the total weight of polymer and plasticizer.
  • the amount of plasticizer is advantageously at most 30% by weight, based on the total weight of polymer and plasticizer, in order to form storage-stable formulations and dosage forms, which do not show any cold flow, in the area of solid forms.
  • Sugar alcohols such as sorbitol, xylitol, mannitol, maltitol; or sugar alcohol derivatives such as isomalt or hydrogenated condensed Palatinose as described in DE 102 62 005.
  • Solubilizers such as sorbitan fatty acid esters, polyalkoxylated fatty acid esters, such as. B polyalkoxylated glycerides, polyalkoxylated sorbitan fatty acid esters or fatty acid esters of polyalkylene glycols; or polyalkoxylated ethers of fatty alcohols.
  • a fatty acid chain in these compounds usually comprises 8 to 22 carbon atoms.
  • the polyalkylene oxide blocks comprise on average from 4 to 50 alkylene oxide units per molecule, preferably ethylene oxide units.
  • Suitable sorbitan fatty acid esters are sorbitan monolaurate, sorbitan monopalmitate, sorbitan monostearate, sorbitan monooleate, sorbitan tristearate, sorbitan trioleate, sorbitan monostearate, sorbitan monolaurate or sorbitan monooleate.
  • Suitable polyalkoxylated sorbitan fatty acid esters are, for example, polyoxyethylene (20) sorbitan monolaurate, polyoxyethylene (20) sorbitan monopalmitate, polyoxyethylene (20) sorbitan monostearate, polyoxyethylene (20) sorbitan monooleate, polyoxyethylene sorbitan tristearate, polyoxyethylene (20) sorbitan trioleate, polyoxyethylene (4) sorbitan monostearate, polyoxyethylene (4) sorbitan monolaurate or polyoxyethylene (4) sorbitan monooleate.
  • Suitable polyalkoxylated glycerides are z. B. obtained by alkoxylation of natural or hydrogenated glycerides or by transesterification of natural or hydrogenated glycerides with polyalkylene glycols.
  • Commercially available examples are polyoxyethylene glycerol ricinoleate-35, polyoxyethylene glycerol trihydroxystearate-40 (Cremophor® RH40, BASF AG) and polyalkoxylated glycerides as are available under the trade names Gelucire® and Labrafil® from Gattefosse, eg.
  • Gelucire® 44/14 (lauroyl-macrogol-32-glycerides prepared by transesterification of hydrogenated palm kernel oil with PEG 1500), Gelucire® 50/13 (stearoyl macrogol-32-glycerides prepared by transesterification of hydrogenated palm oil with PEG 1500 ) or Labrafil M1944 CS (oleoyl-macrogol-6-glycerides prepared by transesterification of apricot kernel oil with PEG 300).
  • a suitable fatty acid ester of polyalkylene glycols is e.g. PEG-660 hydroxy stearic acid (polyglycol ester of 12-hydroxystearic acid (70 mol%) with 30 mol% ethylene glycol).
  • Suitable polyalkoxylated ethers of fatty alcohols are, for. Macrogol-6-cetyl stearyl ether or macrogol-25 cetyl stearyl ether
  • Solubilizers are typically used in an amount of from 0.1 to 15% by weight, preferably from 0.5 to 10% by weight, in the powder mixture.
  • Disintegrants such as crosslinked polyvinylpyrrolidone and crosslinked Natriumcarboxymethyl- cellulose.
  • Extenders or fillers such as lactose, cellulose, silicates or silica
  • Lubricants such as magnesium and calcium stearate, sodium stearyl fumarate,
  • Dyes such as azo dyes, organic or inorganic pigments or dyes of natural origin
  • Stabilizers such as antioxidants, light stabilizers, hydroperoxide destroyers, radical scavengers, stabilizers against microbial attack.
  • the components or a part of the components of the melt are mixed before heating to form a powder mixture.
  • Mixing the grain Components for powder mixing is carried out in conventional mixers, such as plowshare mixers, shaker or free-fall mixers and the like.
  • the heating of the powder mixture takes place in a conventional mixing and plasticizing unit for this purpose.
  • heatable extruders or kneaders such as mixing kneading reactors (eg ORP, CRP, AP, DTB from List or Reactotherm from Krauss-Maffei or Ko-Kneader from Buss), Doppelmulden kneaders (tray mixers) and die kneaders (Internal mixer) or rotor / stator systems (eg Dispax from IKA).
  • the residence time of the mass in the extruder is preferably less than 5 minutes, in particular less than 3 minutes.
  • twin-screw extruders rotating in the same direction or in opposite directions and optionally equipped with kneading disks.
  • co-rotating twin screw extruders are particularly preferred.
  • the feeding of the extruder or kneader takes place, depending on their design, continuously or discontinuously in the usual way.
  • the powder mixture is preferably in the free feed, z. B. be introduced via a differential dosing.
  • the pulverulent mixture of the polymer and the active ingredient is introduced at an inlet end into an elongated extruder housing; heats the mixture to obtain a melt; moves the melt through the extruder barrel to an exit end of the extruder barrel; and generates sufficient back pressure in the extruder barrel to allow the melt to exit from an exit end of the extruder barrel as a continuous extrudate.
  • the resulting composition is subsequently subjected to shaping according to the invention.
  • a multiplicity of shapes depending on the tool and the type of shaping, can be produced.
  • these forms can also be ground to powder and then compressed in the usual way to tablets.
  • tabletting aids such as colloidal silica, calcium hydrogen phosphate, lactose, microcrystalline cellulose, starch or magnesium stearate can be used.
  • the molding rolls usable in the invention for shaping the melt can be cooled or heated in a manner known per se, and the optimum surface temperature of the molding roll for the respective processing can be adjusted in this manner.
  • the invention will be further illustrated with reference to Figures 1 and 2 and by the following examples.
  • FIG. 1a shows a suitable apparatus 1 for carrying out the method according to the invention with counter-rotating forming rollers 2 and 3.
  • the forming rollers 2 and 3 have recesses 4 and 5 on their surface.
  • On the lateral surface of the forming rollers 2 and 3 is a release film 7.
  • the release film 7 is pressed in the nip in the wells 4 and 5. After leaving the nip, the portions of the melt 6 are removed from the mold.
  • FIG. 1 b shows an enlarged detail of the gap between the forming rollers 2 and 3 from FIG. 1 a and shows the separating film 7 in its rest position 8 or its deflected position 9.
  • Adjustable guide rollers 10 make it possible to guide the separating films 7 at a distance from the forming rollers 2 and 3 outside the nip. Adjusted to the guide rollers 10 screws 11 and 12 (not shown in FIG. 2) allow the distance between the guide rollers 10 to vary and thus the tension of the release film 7, when using elastic bands to set a precise adjustment of the thickness of the release film 7 in the nip examples :
  • a mixture containing 50% by weight of verapamil hydrochloride, 32% by weight of hydroxypropylcellulose (Klucel EF, Aqualon) and 18% by weight of hydroxypropylmethylcellulose (Methocel K4M; Colorcon) was used in a co-rotating twin-screw extruder at a screw speed extruded from 80 U / min and a melt product temperature of 110 - 120 0 C to a homogeneous extrudate melt.
  • the melt came directly after exiting the extruder head between a pair of counter-rotating mold rolls, the molding rolls each had recesses on their surface, with the help of which in the nip from the melt directly tablets could be formed.
  • the forming rolls were coated with an annular elastomeric film which had been cut out of the gum area of a rubber glove (Duo-Nit Co., material: latex mix, film thickness: 0.4 mm).
  • This elastomeric ring had a slightly smaller diameter than the forming rolls in the unstretched state and therefore sat firmly on the forming roll surface in a slightly stretched state.
  • a Formwalzentemperatur of 10 ° C could with this process from the active ingredient-containing melt directly elongated tablets of about 1000 mg in weight are produced. There were no problems with melt sticking in the cavities of the forming rolls.
  • Example 2 The procedure was as in Example 1, but without using the elastomeric film on the rollers. The melt adhered too much to the calender roll surfaces, i. a demolding of the tablets did not succeed.
  • Example 2 The procedure was as described in Example 1, but with a mixture consisting of 50 wt .-% verapamil hydrochloride, 40 wt .-% hydroxypropyl cellulose (Klucel EF, Aqualon) and 10 wt .-% hydroxypropyl methylcellulose (Methocel K100M; Colorcon ).
  • the calendering was carried out with an elastomer ring (elastomeric film from the cuff area of a rubber glove, Berner, cytostatics).
  • Rubber glove BI-4021 material: natural latex, foil thickness: 0,26 mm). There were no problems with melt sticking in the cavities of the forming rolls.
  • Example 4 (comparative example): The procedure was carried out as in Example 3, but without the use of the elastomeric film on the rollers. The melt adhered too much to the calender roll surfaces, i. a demolding of the tablets did not succeed.
  • Example 5 The procedure was as described in Example 1, but with a mixture consisting of 55% by weight of hydroxypropylcellulose (Klucel EF, Aqualon) and 45% by weight of mannitol (Merck). The calendering was carried out with an elastomer ring (elastomeric film from the cuff area of a rubber glove, Reichelt Chemie-Technik, Thomastat-HSR-2020 15 MIL black gloves, material: soft plastic, film thickness: 0.15 mm). There were no problems with melt sticking in the cavities of the forming rolls.
  • Example 5 The procedure was carried out as in Example 5, but without the use of the Wael- zen elastomeric film. The melt adhered too much to the calender roll surfaces, i. a demolding of the tablets did not succeed.
  • the melt came directly after exiting the extruder head between a pair of counter-rotating mold rolls, the molding rolls each had depressions on their surface, with the help of which in the nip from the melt directly tablets could be formed.
  • the tablets were readily demoulded using the elastomeric film specified in Example 1. There were no problems with melt sticking in the cavities of the forming rolls.
  • Example 7 The procedure was as in Example 7, but without the use of the rollers on the elastomeric film. The melt adhered too much to the calender roll surfaces, i. a demolding of the tablets did not succeed.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mechanical Engineering (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Extrusion Moulding Of Plastics Or The Like (AREA)
  • Casting Or Compression Moulding Of Plastics Or The Like (AREA)

Abstract

L'invention concerne un procédé permettant de produire des formes de dosage, selon lequel deux films de séparation (7) sont appliqués l'un contre l'autre dans une zone définie, une matière fondue contenant un principe actif est introduite entre les films de séparation (7), de sorte à former dans au moins un des films de séparation (7), une poche pour recevoir une portion de matière fondue, puis les films de séparation (7) sont séparés l'un de l'autre, afin de démouler la portion formée. L'invention concerne de préférence un procédé selon lequel les films de séparation (7) sont appliqués l'un contre l'autre dans l'espace situé entre deux cylindres de moulage (2,3) tournant en sens inverse. Lesdits cylindres de moulage présentent sur leur surface, des cavités (4, 5) opposées, dans lesquelles les films de séparation (7) peuvent être comprimés pour former des poches, lors de l'introduction de la matière fondue contenant le principe actif. La présence des films de séparation (7) évite un contact direct entre la matière fondue et les cylindres (4, 5) et par conséquent l'adhérence de la matière fondue au cylindre (4, 5). Les films de séparation (7) à déformation élastique facilitent le démoulage, de par leur détente une fois qu'ils ont quitté l'espace compris entre les cylindres.
EP06707060.7A 2005-02-17 2006-02-17 Production de formes posologiques à partir de substances actives fondues Active EP1848394B1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP06707060.7A EP1848394B1 (fr) 2005-02-17 2006-02-17 Production de formes posologiques à partir de substances actives fondues

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05003457A EP1693045A1 (fr) 2005-02-17 2005-02-17 Production de formes posologiques à partir de substances actives fondues
PCT/EP2006/001475 WO2006087218A1 (fr) 2005-02-17 2006-02-17 Production de formes de dosage a partir de matieres fondues contenant un principe actif
EP06707060.7A EP1848394B1 (fr) 2005-02-17 2006-02-17 Production de formes posologiques à partir de substances actives fondues

Publications (2)

Publication Number Publication Date
EP1848394A1 true EP1848394A1 (fr) 2007-10-31
EP1848394B1 EP1848394B1 (fr) 2013-10-09

Family

ID=34933806

Family Applications (2)

Application Number Title Priority Date Filing Date
EP05003457A Withdrawn EP1693045A1 (fr) 2005-02-17 2005-02-17 Production de formes posologiques à partir de substances actives fondues
EP06707060.7A Active EP1848394B1 (fr) 2005-02-17 2006-02-17 Production de formes posologiques à partir de substances actives fondues

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP05003457A Withdrawn EP1693045A1 (fr) 2005-02-17 2005-02-17 Production de formes posologiques à partir de substances actives fondues

Country Status (7)

Country Link
US (1) US20090050262A1 (fr)
EP (2) EP1693045A1 (fr)
JP (1) JP2008529852A (fr)
CA (1) CA2598168C (fr)
DK (1) DK1848394T3 (fr)
ES (1) ES2445828T3 (fr)
WO (1) WO2006087218A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090317355A1 (en) * 2006-01-21 2009-12-24 Abbott Gmbh & Co. Kg, Abuse resistant melt extruded formulation having reduced alcohol interaction
TW200950776A (en) * 2008-01-24 2009-12-16 Abbott Gmbh & Co Kg Abuse resistant melt extruded formulation having reduced alcohol interaction
US9226907B2 (en) 2008-02-01 2016-01-05 Abbvie Inc. Extended release hydrocodone acetaminophen and related methods and uses thereof
CN108309796A (zh) * 2018-01-17 2018-07-24 刘雅文 一种压缩中药饮片及其制备方法
KR102585933B1 (ko) * 2022-09-21 2023-10-06 주식회사 태성공영 구형 성형체 제조장치
CN117698024B (zh) * 2023-12-18 2024-06-25 青岛环球输送带有限公司 一种节能式橡胶硫化机

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5722900A (en) * 1980-07-12 1982-02-05 Kurosaki Refract Co Ltd Pocket structure in roll or the like for briquetting machine
SU1600670A2 (ru) * 1987-12-03 1990-10-23 Кемеровский технологический институт пищевой промышленности Устройство дл формовани конфетных масс
JPH0263699A (ja) * 1988-08-29 1990-03-02 Fuji Paudaru Kk 圧縮造粒装置
DE3830353A1 (de) 1988-09-07 1990-03-15 Basf Ag Verfahren zur kontinuierlichen herstellung von festen pharmazeutischen formen
RU1824158C (ru) * 1991-03-11 1993-06-30 Кемеровский технологический институт пищевой промышленности Устройство дл формовани конфетных масс
DE4446467A1 (de) 1994-12-23 1996-06-27 Basf Ag Verfahren zur Herstellung von linsenförmigen Tabletten durch Schmelzkalandrierung
DE4446468A1 (de) * 1994-12-23 1996-06-27 Basf Ag Verfahren zur Herstellung von umhüllten Tabletten
DE19531277A1 (de) 1995-08-25 1997-02-27 Basf Ag Verwendung von Lipiden als Hilfsmittel bei der Herstellung von festen Arzneiformen nach dem Schmelzextrusionsverfahren
DE10242062B4 (de) 2002-09-11 2007-02-15 Südzucker Aktiengesellschaft Mannheim/Ochsenfurt Hydrierte kondensierte Palatinose, Verfahren zu deren Herstellung und deren Verwendung

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2006087218A1 *

Also Published As

Publication number Publication date
WO2006087218A1 (fr) 2006-08-24
CA2598168A1 (fr) 2006-08-24
EP1693045A1 (fr) 2006-08-23
ES2445828T3 (es) 2014-03-05
EP1848394B1 (fr) 2013-10-09
CA2598168C (fr) 2014-09-23
US20090050262A1 (en) 2009-02-26
JP2008529852A (ja) 2008-08-07
DK1848394T3 (da) 2014-01-20

Similar Documents

Publication Publication Date Title
EP0864324B1 (fr) Méthode pour la production de formes pharmaceutiques solides combinées
EP1237703B1 (fr) Procede de production de corps moules solides contenant un principe actif
EP0998920B1 (fr) Procede de production de formes solides de dosage
EP0857062B1 (fr) Procede de preparation de formes galeniques solides multicouches pour administration orale ou rectale
EP0993828B1 (fr) Procédé pour produire des formes de dosage solides enrobées
EP0864326B1 (fr) Préparation multiphasique comprenant un agent actif
EP2114375B1 (fr) Agent d'enrobage sous forme de film, formé de particules à dispersion rapide, à base de copolymères greffés de polyvinylalcool-polyéther
EP0820753A2 (fr) Procédé de fabrication de produits pharmaceutiques solides
EP1107739B1 (fr) Procede de preparation de formes posologiques solides
EP0998918A2 (fr) Forme galenique solide contenant un liant copolymère
EP1848394B1 (fr) Production de formes posologiques à partir de substances actives fondues
EP1143910B1 (fr) Procede et dispositif pour produire differentes formes galeniques solides
EP1556012B1 (fr) Production de formes galeniques solides au moyen d'un excipient non thermoplastique reticule
EP1748762B1 (fr) Forme de dosage obtensible à partir d'un mélange de poudres contenant un pigment inorganique
EP0931552A2 (fr) Procédé de préparation de formes solides de dosage
WO1997015291A1 (fr) Procede de preparation de formes galeniques solides
WO2008080773A1 (fr) Procédé de production de formes galéniques solides contenant des copolymères greffés
EP0998919A2 (fr) Forme galenique solide contenant un liant copolymère
WO1997015290A1 (fr) Procede de preparation de formes galeniques solides

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070817

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20130506

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

Free format text: NOT ENGLISH

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

Ref country code: AT

Ref legal event code: REF

Ref document number: 635238

Country of ref document: AT

Kind code of ref document: T

Effective date: 20131015

RAP2 Party data changed (patent owner data changed or rights of a patent transferred)

Owner name: ABBVIE DEUTSCHLAND GMBH & CO KG

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

Free format text: LANGUAGE OF EP DOCUMENT: GERMAN

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 502006013257

Country of ref document: DE

Effective date: 20131212

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20140113

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: BOHEST AG, CH

REG Reference to a national code

Ref country code: NL

Ref legal event code: VDEP

Effective date: 20131009

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20131009

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2445828

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20140305

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20131009

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20131009

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140209

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20131009

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20131009

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20131009

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20131009

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140210

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 502006013257

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20131009

REG Reference to a national code

Ref country code: CH

Ref legal event code: PCAR

Free format text: NEW ADDRESS: HOLBEINSTRASSE 36-38, 4051 BASEL (CH)

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20131009

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20131009

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20131009

26N No opposition filed

Effective date: 20140710

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20131009

Ref country code: LU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140217

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 502006013257

Country of ref document: DE

Effective date: 20140710

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 11

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20131009

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140110

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20131009

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20060217

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 12

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 13

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230331

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20240306

Year of fee payment: 19

Ref country code: IE

Payment date: 20240126

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20240126

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20240109

Year of fee payment: 19

Ref country code: CH

Payment date: 20240301

Year of fee payment: 19

Ref country code: GB

Payment date: 20240111

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20240208

Year of fee payment: 19

Ref country code: IT

Payment date: 20240213

Year of fee payment: 19

Ref country code: FR

Payment date: 20240108

Year of fee payment: 19

Ref country code: DK

Payment date: 20240130

Year of fee payment: 19

Ref country code: BE

Payment date: 20240110

Year of fee payment: 19